| DB ID | MyCo_5474 |
| Title | Evaluation of the new AspID polymerase chain reaction assay for detection of Aspergillus species: A pilot study |
| Year | 2018 |
| PMID | 29460450 |
| Fungal Diseases involved | Invasive pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | Lungs |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | The accuracy of the AspID was determined utilising the QCMD 2016 Aspergillus spp. DNA EQA Programme panel. The panel consisted of 9 members including Aspergillus fumigatus DNA (n = 3), Aspergillus fumigatus conidia (n = 3), and negatives (n = 3). Members were either spiked in TE puffer, synthetic sputum, or in plasma matrix. In addition, 36 BALF samples obtained from 18 patients with IPA and 18 patients without IPA were investigated. Samples were obtained between 2013 and 2016 at the Medical University of Graz, Austria. BALF samples were stored at −70°C immediately after collection and have—in part—been used in studies published recently.4,6,13-15 Patients were classified as having IPA if BALF galactomannan (GM) levels showed an optical density index of >3.0 and patients had clinical and radiological findings compatible with presence of IPA, as suggested by D’Haese and colleagues.16 Patients without IPA had BALF-GM levels of <0.5 and no clinical or radiological findings suggestive for presence of IPA. Patients were matched 1:1 according to IPA status, primary underlying disease, and intensive care unit admission. |
| Cohort No. | 18 |
| Age Group | 48-84 |
| P Value | None |
| Sensitivity | 0.941 |
| Specificity | 0.765 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive pulmonary aspergillosis (IPA) remains a major cause of morbidity and mortality among severely ill patients. The critical step for successful management of IPA is rapid initiation of antifungal therapy requiring early and reliable diagnosis Several diagnostic approaches including antigen testing, new imaging methods and molecular approaches have been investigated to overcome current limitations, such as limited performance of available diagnostic methods, long turnaround times, and/or limited standardisation. Over recent years, Aspergillus polymerase chain reaction (PCR) has been shown to be a very promising tool for detection of fungal infections when testing bronchoalveolar lavage fluid (BALF) from immunocompromised patients.6-11 The newly developed AspID (OLM Diagnostics, Newcastle, UK) assay is a multiplex real-time PCR assay designed to detect clinically relevant Aspergillus spp. This assay targets a pan Aspergillus target and simultaneously an Aspergillus terreus target for differentiation of Aspergillus terreus vs non-terreus Aspergillus spp. This is of particular interest as changing epidemiology with an increase in non-fumigatus Aspergillus infections has been observed over the past decades. |
| Technique | PCR |
| Analysis Method | AspID PCR assay |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
